1 tical analysis plan for the primary endpoint
was amended to a combined analysis of cohorts 1 and 2 (i
2 10, 2008, in response to new data, the trial
was amended to a prospectively stratified design, restri
3 observed declining event rate, the protocol
was amended to a time-based analysis.
4 mab induction group was closed and the study
was amended to a two-arm study.
5 closed early on Sept 30, 2007, and the study
was amended to a two-arm trial.
6 Moreover, regulatory standards may need to
be amended to accommodate the unique characteristics of
7 The fluid mosaic model has recently
been amended to account for the existence of membrane do
8 On June 20, 2014, the protocol
was amended to allow 7 out of 8 matched unrelated donors
9 The protocol
was amended to allow additional patients to be treated w
10 On May 30, 2012, the study protocol
was amended to allow crossover from control to trastuzum
11 median follow-up of 14 months), the protocol
was amended to allow for unblinding sites to treatment a
12 The protocol
was amended to allow patients in the investigator's choi
13 On Sept 12, 2012, the study protocol
was amended to allow patients with disease progression t
14 Subsequently, the protocol
was amended to assess OS by unadjusted log-rank test aft
15 ned enrollment of 252 patients, the protocol
was amended to continue with a three-arm design (1:1:6 r
16 Drug laws need to
be amended to ensure the safety and effectiveness of med
17 The study
was amended to exclude CR patients from receiving alemtu
18 The study protocol
was amended to exclude patients with prior hematopoietic
19 study of people of European ancestry, which
was amended to exclude UK BioBank data.
20 During the study the protocol
was amended to extend PR to 48 weeks for patients with p
21 From patient 50 onwards, the study protocol
was amended to fractionate inotuzumab ozogamicin to a ma
22 As such, the method of administration
was amended to have a maximum infusion time of 60 minute
23 to protracted patient accrual, the protocol
was amended to have a single primary endpoint of indepen
24 both R. dentocariosa and C. aurimucosum have
been amended to include charcoal-black-pigmented variant
25 The protocol
was amended to include a blinded crossover.
26 For the trial ACOSOG Z1031B, the protocol
was amended to include a tumor Ki67 determination after
27 of the vaccine was authorized, the protocol
was amended to include an open-label phase.
28 ations inducing resistance to AIs, the trial
was amended to include cohort 2, in which patients were
29 The protocol
was amended to include pegfilgrastim because of dose-lim
30 e-response correlation, the phase II portion
was amended to include several dose levels.
31 On April 6, 2011, the protocol
was amended to include three additional patients in the
32 additional toxicity was observed, the study
was amended to include two additional EOC + P dose level
33 The studies
were amended to include a joint analysis comparing group
34 pletion of the planned accrual, the protocol
was amended to introduce a third arm with rituximab alon
35 the fluency theory of aesthetic pleasure can
be amended to meet the requirements of the framework.
36 After a feasibility analysis, the study
was amended to reduce cisplatin to two cycles during CCR
37 The study
was amended to reduce the starting dose of irinotecan to
38 8l has
been amended to remove the term 'pericyte mimicry' that
39 Both studies
were amended to remove rituximab, but two of three addit
40 This can
be amended to routine clinical scans and may help in ear
41 21 days for four cycles, until the protocol
was amended to six cycles.
42 requested that the Acknowledgements section
be amended to thank Weidi Yang for his assistance with t
43 FF formulations, PFASs, and ethylene glycols
were amended to the growth medium of a D. mccartyi-conta
44 The protocol then
was amended to treat the prostate volume first followed
45 d RP2D were not established as the trial has
been amended to utilize an automated manufacturing proce